IMR Press / EJGO / Volume 24 / Issue 1 / pii/2003105

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Frequent disease progression and early recurrence in patients with familial ovarian cancer primarily treated with paclitaxel and cis- or carboplatin (preliminary report)

Show Less
1 Genetic Counselling Unit, Great Poland Cancer Center, Poznań, Poland
2 Division of Gynecological Oncology, Department of Oncology, Medical School, Poznań
3 Department of Endocrinology, Warszawa, Poland
4 Department of Immunology, M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warszawa, Poland
Eur. J. Gynaecol. Oncol. 2003, 24(1), 21–24;
Published: 10 February 2003

Purpose: To evaluate frequencies of early disease progressions and recurrences in patients with familial vs sporadic ovarian cancers following primary paclitaxel/cis- or carboplatin chemotherapy Methods: The frequencies of disease progression up to six months following primary paclitaxel/cis- or carboplatin and of early disease recurrences were analysed in 18 Stage III patients with familial ovarian cancers, both carriers and non-carriers of 5382 insC BRCAJ mutation, and in 35 patients with Stage III sporadic ovarian tumors. Results: Progressive disease within first six months following chemotherapy developed in 5/18 patients with familial cancers vs. 5/35 patients with sporadic tumors. Early disease recurrences (up to 6 months after treatment) occurred in 3/18 patients with familial vs. 2/35 patients with sporadic tumors. Recurrences after 7-12 months following treatment occurred, respectively, in 3/13 and 3/31 patients from these groups. Conclusion: The results of this preliminary report may suggest that patients with familial ovarian tumors respond less favourably to paclitaxel/cis- or carboplatin treatment than patients with sporadic ovarian tumors. These findings should be however confirmed in a prospective study on a larger group of patients.

Familial ovarian cancer
BRCAJ mutations
Primary treatment failures
Back to top